KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Common Equity (2019 - 2025)

Royalty Pharma's Common Equity history spans 7 years, with the latest figure at $9.7 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 6.07% year-over-year to $9.7 billion; the TTM value through Dec 2025 reached $9.7 billion, down 6.07%, while the annual FY2025 figure was $9.7 billion, 6.07% down from the prior year.
  • Common Equity for Q4 2025 was $9.7 billion at Royalty Pharma, up from $9.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $10.4 billion in Q3 2022 and bottomed at $9.5 billion in Q2 2025.
  • The 5-year median for Common Equity is $9.9 billion (2021), against an average of $10.0 billion.
  • The largest annual shift saw Common Equity skyrocketed 37.34% in 2021 before it dropped 7.98% in 2023.
  • A 5-year view of Common Equity shows it stood at $10.2 billion in 2021, then dropped by 7.06% to $9.5 billion in 2022, then increased by 5.87% to $10.1 billion in 2023, then increased by 2.56% to $10.3 billion in 2024, then decreased by 6.07% to $9.7 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Common Equity are $9.7 billion (Q4 2025), $9.6 billion (Q3 2025), and $9.5 billion (Q2 2025).